A new poll of more than 1,400 people who work in the biotech and pharmaceutical industries by John Carroll of Endpoints News reveals a clear consensus: The FDA made a big mistake approving Aduhelm, Biogen's Alzheimer's treatment, and the $56,000 price tag does not match any possible benefit.
Why it matters: Even the industry's own experts are not defending the FDA and Biogen.
Stay on top of the latest market trends and economic insights with Axios Markets. Subscribe for free
What they're saying: Many of the submitted comments are worth reading in full, but this one captured the general tenor of the responses Endpoints received:
"Aducanumab priced at $56k with the efficacy of a sugar pill is taking advantage of patients, the health care system and is ruthless," one commenter said.
Like this article? Get more from Axios and subscribe to Axios Markets for free.